Chelsea Presson, NP
Primary Care · Little Rock, ARNPI 1548749906
Payments from drug & device makers
Across 543 payments — averaging $40.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$11K
- Argenx US, Inc.$3K
- AbbVie$2K
- UCB, Inc.$930
- Novartis$754
- Amneal Pharmaceuticals LLC$502
- plus $4K from 29 others
What the payments were for
- Consulting fees$2,0759%
- Speaking & faculty fees$7,36533%
- Travel & lodging$3,01114%
- Food & beverage$9,54643%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 40 | $10,536 |
| Argenx US, Inc. | 24 | $2,915 |
| AbbVie | 146 | $2,372 |
| UCB, Inc. | 36 | $930 |
| Novartis | 46 | $754 |
| Amneal Pharmaceuticals LLC | 39 | $502 |
| Lundbeck LLC | 26 | $461 |
| AstraZeneca(2 entities) | 20 | $375 |
| MDD US Operations, LLC | 17 | $323 |
| Merz Pharmaceuticals, LLC | 15 | $306 |
| CSL Behring | 16 | $303 |
| Biogen | 13 | $244 |
| Biohaven Pharmaceuticals, Inc. | 10 | $240 |
| Lilly USA, LLC | 17 | $236 |
| Amgen | 10 | $225 |
| Genentech USA, Inc. | 7 | $134 |
| Springworks Therapeutics, Inc. | 4 | $125 |
| Eisai Inc. | 6 | $121 |
| Ipsen Biopharmaceuticals, Inc | 5 | $101 |
| Bristol Myers Squibb | 6 | $98 |
| Impel Pharmaceuticals Inc. | 4 | $83 |
| Neurocrine Biosciences, Inc. | 5 | $78 |
| Livanova USA, Inc. | 3 | $76 |
| TG Therapeutics, Inc. | 4 | $74 |
| Sanofi | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $72 |
| Tanabe Pharma America, Inc. | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| SK Life Science, Inc. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| NS Pharma, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$10,136
- VYVGART HYTRULO$2,296
How this compares
$22,052 in reported general payments places this provider in the 95th percentile of 76 primary care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 13 | $678,522 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $125,344 |
| NuplazidPimavanserin Tartrate | 24 | $117,121 |
| Nurtec OdtRimegepant Sulfate | 48 | $82,810 |
| Emgality SyringeGalcanezumab-Gnlm | 31 | $75,485 |
| CopaxoneGlatiramer Acetate | 13 | $74,599 |
| Emgality PenGalcanezumab-Gnlm | 60 | $66,976 |
| UbrelvyUbrogepant | 28 | $34,241 |
| QuliptaAtogepant | 30 | $34,143 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $14,419 |
| MounjaroTirzepatide | 12 | $12,687 |
| Nortriptyline Hcl | 129 | $2,010 |
| Ropinirole Hcl | 88 | $1,794 |
| Gabapentin | 133 | $1,743 |
| Levetiracetam | 38 | $1,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $375 | $678,52213 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $39 | $125,34413 claims |
| PfizerNurtec Odt | $10,536 | $82,81048 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $62 | $74,59913 claims |
| AbbVieUbrelvy, Qulipta | $2,372 | $68,38458 claims |
| Lilly USA, LLCMounjaro | $236 | $12,68712 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $502 | $1,21921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 primary care providers in Arkansas.
Other primary care in Little Rock
- Katherine ThompsonLittle Rock$10K
- Krystalyn WilliamsLittle Rock$3K
- Vallon WilliamsLittle Rock$2K
- Katherine KnightLittle Rock$551
- Jamie FergusonLittle Rock$146
- Meagan RipleyLittle Rock$120
- Christy ReedLittle Rock$101
- Andrew OliverMaumelle$45K
- Stephen RohrerWynne$15K
- Chelsea MarquisSpringdale$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.